Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · IDRCB
interventional
150
1 country
2
Study Start
February 20, 2017
Actual (reported)Primary Completion
February 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Psychiatric disturbances, notably depression, occur frequently as co-morbid conditions with epilepsy. A complex, probably bidirectional relationship between epilepsy and depression has been postulated. Both epilepsy and depression also interact with stressful life events, but only some patients develop these disorders after a stressful event, indicating the possibility of a "vulnerable" population. Animal and human studies have looked at the role of brain derived neurotrophic factor (BDNF) in this context. Low serum and/or CSF levels of BDNF are associated with higher incidence of depression, and thus indicate the vulnerable population. Animal studies of BDNF have looked specifically at the relation between epilepsy and depression using a novel "double hit" design. After chronic stress exposure, measurement of BDNF levels allowed identification of 2 sub-groups: a vulnerable population and non-vulnerable population. A "second hit" of kainic acid induced status epilepticus (SE) was then applied to both the vulnerable and non-vulnerable populations. Only the vulnerable population exposed to SE developed a depression-like profile. In a proof of concept approach we propose studying the relation between epilepsy, depression, anxiety and stressful life events, using serum BDNF levels in patients with pharmacoresistant epilepsy. Evaluation of epilepsy type and co-morbid psychiatric profile will be performed in 150 subjects. By comparing BDNF levels for different epilepsy subgroups to BDNF levels for healthy subjects and for depressed subjects without epilepsy, we hope to identify whether risk of co-morbid depression and/or anxiety in epilepsy may be predicted using BDNF levels. In addition, in a subgroup of 25 patients, we propose a pilot study in which cortisol and C-reactive protein will be measured in addition to BDNF.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 20, 2017
Actual (reported)August 7, 2017
Actual (reported)August 9, 2017
Actual (reported)February 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Depression
Score assessment of Becks Depression Inventory sacle
24 months
Patient will answer self-questionner on Depression
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Assistance Publique Hôpitaux de Marseille
Marseille, 13354, France
Chu Tours
Tours, France
Urielle DESALBRES
Assistance Publique Hôpitaux de Marseille
First Submitted
August 7, 2017
First Posted
August 9, 2017
Study Start
February 20, 2017
Actual (reported)Primary Completion
February 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Study Completion
February 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 9, 2017
Record last verified: 2017-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: